EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis

Catharina J P Op 't Hoog iD, Sabien J E Bosman, Emmy Boerrigter iD, Niven Mehra, Inge M van Oort, Nielka P van Erp, Wietske Kievit

Therapeutic Advances in Medical Oncology · 2024-01 · 16

DOI: 10.1177/17588359241305084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 15.12.2024. Verfasst von Catharina J P Op 't Hoog und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The androgen receptor pathway inhibitors (ARPI), abiraterone acetate and enzalutamide, are commonly used in first-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). However, early resistance to ARPI treatment occurs frequently. Traditionally, the response is evaluated 3–6 months after the start of treatment. However, recent findings indicate that by detecting circulating tumor DNA (ctDNA) at baseline and 4 weeks after ARPI treatment initiation, patients with a nondurable response can be identified after 4 weeks of treatment, enabling an early switch to alternative treatments.

Objective

This study aims to evaluate the cost-effectiveness of ctDNA-guided treatment switch after 4 weeks of ARPI therapy in mCRPC patients compared to standard of care.

Design

A cost-effectiveness analysis.

Methods

A cost-effectiveness analysis was conducted by creating a Markov state transition model to simulate progression, mortality, and treatment costs over a 5-year time horizon comparing ctDNA-guided care versus standard of care. The outcomes measured were incremental treatment costs per life-years and quality-adjusted life-years (QALYs) gained.

Results

The analysis showed an incremental cost-effectiveness ratio of €65,400.86 per QALY gained and an incremental net monetary benefit of €2716.62. Thereby, the use of ctDNA-guided treatment was cost-effective in comparison to standard care in 74% of the simulations using a willingness-to-pay threshold of €80,000 per QALY gained.

Conclusion

Our study demonstrated the cost-effectiveness of using a ctDNA-guided early therapy switch in non-responders after only 4 weeks of first-line ARPI therapy in mCRPC patients. This paves the way for implementing ctDNA-guided treatment decisions in clinical practice.

Schlagwörter

Stichwörter der Autor:innen

androgen receptor pathway inhibitorsbiomarkerschemotherapycirculating tumor DNA (ctDNA)cost-effectiveness analysishealth services researchhormone therapyliquid biopsyprostate cancer

Autor:innen und Institutionen

  • Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • IQ Health, Research Institute for Medical Innovation, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Urology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • IQ Health (160), Research Institute for Medical Innovation, Radboud University Medical Center, P.O. Box 9101, Nijmegen 6500 HB, The Netherlands.
  • IQ Health, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.

ORCID-Profile: Catharina J P Op 't Hoog, Emmy Boerrigter

Förderung

  • ZonMw

Zitieren

APA

Op 't Hoog, C. J. P., Bosman, S. J. E., Boerrigter, E., Mehra, N., van Oort, I. M., van Erp, N. P., & Kievit, W. (2024). Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241305084

Vancouver

Op 't Hoog CJP, Bosman SJE, Boerrigter E, Mehra N, van Oort IM, van Erp NP, et al. Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241305084

BibTeX
@article{OptHoog2024,
  author = {Op 't Hoog, Catharina J P and Bosman, Sabien J E and Boerrigter, Emmy and Mehra, Niven and van Oort, Inge M and van Erp, Nielka P and Kievit, Wietske},
  title = {Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17588359241305084}
}
Kostenlos starten →